A recent study found that tumors in mice shrank after being treated with tirzepatide, a GLP-1 agonist drug. While the study was modest in scope and conducted on mice, the results are promising and suggest potential for cancer treatment. Eli Lilly’s GLP-1 drugs, Zepbound and Mounjaro, have been performing well, with sales soaring 45% in the first three months of 2025. If these drugs receive regulatory approval for cancer treatment, it could lead to significant sales growth for Eli Lilly. Despite the stock trading at a premium, it may be a strong long-term investment with potential for growth in the healthcare sector.

Read more at Nasdaq: Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might